MX2010006287A - Peptidomimeticos con actividades antagonistas de glucagon y agonistas del peptido 1 similar al glucagon. - Google Patents

Peptidomimeticos con actividades antagonistas de glucagon y agonistas del peptido 1 similar al glucagon.

Info

Publication number
MX2010006287A
MX2010006287A MX2010006287A MX2010006287A MX2010006287A MX 2010006287 A MX2010006287 A MX 2010006287A MX 2010006287 A MX2010006287 A MX 2010006287A MX 2010006287 A MX2010006287 A MX 2010006287A MX 2010006287 A MX2010006287 A MX 2010006287A
Authority
MX
Mexico
Prior art keywords
peptidomimetics
glp
agonistic activities
glucagon antagonistic
glucagon
Prior art date
Application number
MX2010006287A
Other languages
English (en)
Inventor
Rajesh H Bahekar
Mukul R Jain
Pankaj Ramanbhal Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2010006287A publication Critical patent/MX2010006287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona peptidomiméticos novedosos de fórmula (I), que actúan principalmente como secretagogos de la insulina dependientes de la glucosa. Además, se encontró que estos peptidomiméticos muestran actividad antagonista del receptor del glucagon, junto con la actividad agonista del receptor de GLP-1.
MX2010006287A 2007-12-11 2008-12-10 Peptidomimeticos con actividades antagonistas de glucagon y agonistas del peptido 1 similar al glucagon. MX2010006287A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2420MU2007 2007-12-11
IN1696MU2008 2008-08-11
PCT/IN2008/000831 WO2009125424A2 (en) 2007-12-11 2008-12-10 Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities

Publications (1)

Publication Number Publication Date
MX2010006287A true MX2010006287A (es) 2010-10-26

Family

ID=41066190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006287A MX2010006287A (es) 2007-12-11 2008-12-10 Peptidomimeticos con actividades antagonistas de glucagon y agonistas del peptido 1 similar al glucagon.

Country Status (15)

Country Link
US (1) US8883963B2 (es)
EP (1) EP2231701B1 (es)
JP (1) JP5270687B2 (es)
KR (1) KR101277560B1 (es)
AT (1) ATE554098T1 (es)
CA (1) CA2707448C (es)
DK (1) DK2231701T3 (es)
EA (1) EA018000B1 (es)
ES (1) ES2382579T3 (es)
IL (1) IL206252A0 (es)
MX (1) MX2010006287A (es)
NI (1) NI201000095A (es)
PT (1) PT2231701E (es)
WO (1) WO2009125424A2 (es)
ZA (1) ZA201003804B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
CN104744370A (zh) 2011-02-08 2015-07-01 辉瑞大药厂 胰高血糖素受体调节剂
ES2550345T3 (es) 2011-07-22 2015-11-06 Pfizer Inc. Moduladores del receptor de quinolinilglucagón
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
BR112016013157A2 (pt) * 2013-12-13 2017-09-26 Medimmune Ltd peptídeos resistentes à protease
WO2015168135A1 (en) * 2014-04-28 2015-11-05 The Trustees Of The University Of Pennsylvania Novel thioamide-modified peptides and uses thereof
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CA2463908A1 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AP2007004227A0 (en) * 2005-05-05 2007-12-31 Cadila Healthcare Ltd Novel compounds as GLP-1 agonists
JP2008539735A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
EP1976873A2 (en) * 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2084182B1 (en) * 2006-10-03 2013-08-28 Cadila Healthcare Limited Antidiabetic compounds

Also Published As

Publication number Publication date
PT2231701E (pt) 2012-05-28
NI201000095A (es) 2011-05-04
ES2382579T3 (es) 2012-06-11
KR20100101110A (ko) 2010-09-16
EP2231701B1 (en) 2012-04-18
DK2231701T3 (da) 2012-05-21
CA2707448A1 (en) 2009-10-15
IL206252A0 (en) 2010-12-30
ATE554098T1 (de) 2012-05-15
US8883963B2 (en) 2014-11-11
ZA201003804B (en) 2011-01-26
JP2011506428A (ja) 2011-03-03
KR101277560B1 (ko) 2013-06-25
EA018000B1 (ru) 2013-04-30
WO2009125424A3 (en) 2009-12-23
EA201070722A1 (ru) 2010-12-30
WO2009125424A2 (en) 2009-10-15
CA2707448C (en) 2014-10-14
US20120021972A1 (en) 2012-01-26
EP2231701A2 (en) 2010-09-29
JP5270687B2 (ja) 2013-08-21

Similar Documents

Publication Publication Date Title
IL206252A0 (en) Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
MX2009003400A (es) Compuestos antidiabeticos.
TN2012000560A1 (en) Glucagon analogues
ECSP11011149A (es) Agonistas del receptor gpr120 y usos de los mismos
PH12014501336A1 (en) Glucagon analogues
MX2018005129A (es) Agonistas del receptor de glucagon.
MY193616A (en) Gip and glp-1 co-agonist compounds
ECSP11010989A (es) Agonistas del receptor gpr120 de arilo y usos de los mismos
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
GEP20146056B (en) Acylated glucagon analogues
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX347703B (es) Co-agonistas del receptor de glucagon/glp-1.
TN2012000567A1 (en) Glucagon analogues
TN2011000160A1 (en) Combination of an insulin and a glp -1 agonist
WO2012015975A3 (en) Glp-1 receptor agonist compounds having stabilized regions
MX2009010970A (es) Moduladores selectivos del receptor de andógenos para el tratamiento de la diabetes.
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201590065A1 (ru) Аналоги глюкагона, проявляющие активность на рецепторе gip
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
EA200702169A1 (ru) Профилактика вич-инфекции
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
CR11730A (es) Compuestos de anillo fusionados y uso de los mismos
UA93387C2 (ru) Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq
UA101297C2 (ru) Замещенное циклическое соединение, способ его получения и его медицинское применение
CO6310997A2 (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina metodos para obtenerlos y uso para el tratamiento de diabetes

Legal Events

Date Code Title Description
FG Grant or registration